

TERAPIO

Recently Funded Terapio Expands Team

Charles Dowding, PhD joins as VP, Preclinical Programs and Vadim Klyushnichenko, PhD joins as VP, Drug Development

AUSTIN, TX – December 7, 2009 – Terapio, an Austin-based biotechnology company, announced today the addition of Charles Dowding and Vadim Klyushnichenko. This comes after last week's announcement that the company received \$5 million in financing from Austin-based venture capital firm, Santé Ventures.

Charles Dowding, PhD

Charles Dowding, PhD is Vice President, Preclinical Programs at Terapio. Dr. Dowding has over 15 years of experience in biopharmaceutical preclinical development of small molecule, cell and cell-based gene products. Dr. Dowding developed his managerial and scientific acumen working as Vice President of Research at The Assay Depot, Vice President of Hematology and Immunology at Hollis-Eden, Director of Cell Product and Process Development at SyStemix/Novartis and as a Research Scientist at QLT. Dr. Dowding received his BS in Applied Biology from Salford University (UK) and PhD in Tumor Stem Cell Biology from Imperial College, London (UK). Dr. Dowding continued his academic research on tumor stem cells as a Postdoctoral Research Fellow at the University of British Columbia (Canada). Dr. Dowding has significant experience and expertise in developing radiation countermeasures; while at Hollis-Eden he was responsible for all preclinical mechanism-of-action and in vivo efficacy studies for the candidate radiation countermeasure Neumune. Dr. Dowding led Hollis-Eden's radiation countermeasure project team for five years, advancing Neumune from drug candidate through human safety studies.

Vadim Klyushnichenko, PhD

Vadim Klyushnichenko, PhD is Vice President, Drug Development at Terapio. Dr. Klyushnichenko has over 15 years of experience in biopharmaceutical project management, analytical development and formulation, process development, engineering and scale up from pilot to GMP, technology transfer and regulatory filing for oral, injectable, pulmonary drugs and drug/device combinations. His drug delivery experience includes formulation of proteins and small molecules in micro-crystals, micro- and nano-particles, liposomes, degradable matrixes as well as the development of controlled-release systems for oral, injectable, implantable and pulmonary delivery. Dr. Klyushnichenko developed his managerial and scientific capabilities working as Vice President of Pharmaceutical Development at Coldstream Laboratories, Inc., Principal Scientist at Wyeth BioPharma and senior scientist positions at Epic Therapeutics (Baxter), Altus Biologics and Aventis (Sanofi Pasteur). Dr. Klyushnichenko received his BS in Physics from Moscow Institute of Physics and Technology and PhD in Chemistry from Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry (Russian Academy of Sciences, Moscow). Dr. Klyushnichenko continued his academic research in Analytical Biochemistry and Process Development as a DAAD Postdoctoral Researcher at Humboldt University in Berlin and a Alexander von Humboldt Fellow at Dusseldorf University as well as Scientist at Biotechnology Research Institute, BioProcess Sector (Montreal, QC Canada). Dr. Klyushnichenko is a Certified Professional Project

Manager and holds a Certificate of Special Studies in Administration and Management from Harvard University.

About Terapio

Terapio is a biopharmaceutical company specialized in the development of a pipeline of therapies based on the naturally-occurring transport protein, RLIP76. Terapio is based in Austin, Texas where it is incubated and funded by Santé Ventures. For more information, visit www.terapio.com.

For More Information, Contact:

Curt Bilby

President & CEO, Terapio

terapio.admin@terapio.com

512.721.1200

###